{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["AVZO-103"]],"indication":"locally advanced or metastatic solid tumors","name":"BEACON-1","nct_id":"NCT07193511","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=beacon-1-nct07193511. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Part A","label":"Phase 1, monotherapy","type":"EXPERIMENTAL"},{"description":"Part B","label":"Phase 1, combination","type":"EXPERIMENTAL"},{"description":"Part A","label":"Phase 2, monotherapy","type":"EXPERIMENTAL"},{"description":"Part B","label":"Phase 2, combination","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2030-09","type":"ESTIMATED"},"conditions":["Solid Tumor Cancer","Locally Advanced","Metastatic Solid Tumors","Urothelial Cancer"],"enrollment":{"count":355,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"AVZO-103","otherNames":[],"type":"DRUG"},{"name":"Combination Agent","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-05","lead_sponsor":"Avenzo Therapeutics, Inc.","official_title":"A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-103, a Nectin4/Trop2 ADC, as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2030-03","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Occurrence of Dose Limiting Toxicities (DLTs) during the first cycle (Phase 1)","timeFrame":"Approximately 2 years"},{"measure":"Determine the maximum tolerated dose (MTD) and/or preliminary recommended Phase 2 dose (RP2D) (Phase 1)","timeFrame":"Approximately 16 months"},{"measure":"Number of Participants with Treatment Emergent Adverse Events (TEAEs) and lab abnormalities (Phase 1)","timeFrame":"From baseline until end of study treatment or study completion (approximately 2 years)"},{"measure":"Objective Response Rate (ORR) (Phase 2)","timeFrame":"From baseline through disease progression or study completion (approximately 2 years)"}],"references":[],"start_date":{"date":"2025-10-02","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)","url":"https://clinicaltrials.gov/study/NCT07193511"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/beacon-1-nct07193511"}